NCT05465785View on ClinicalTrials.gov

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

NACompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

March 11, 2023

Study Completion Date

December 30, 2023

Conditions
COVID-19SARS-CoV-2 Pneumonia
Interventions
BIOLOGICAL

Recombinant COVID-19 vaccine (Sf9 cell)

This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Huai'an

All Listed Sponsors
lead

WestVac Biopharma Co., Ltd.

INDUSTRY